Factors Affecting Steady-state Plasma Concentrations of Enantiomeric Mirtazapine and its Desmethylated Metabolites in Japanese Psychiatric Patients

Pharmacopsychiatry

Volumn 48, Issue 7, 2015, Pages 279-285

  Hayashi, Y ^a   Watanabe, T ^a   Aoki, A ^a   Ishiguro, S ^a   Ueda, M ^a   Akiyama, K ^a   Kato, K ^b   Inoue, Y ^a   Tsuchimine, S ^c   Yasui Furukori, N ^c   Shimoda, K ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b Sakura la Mental Clinic   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

CYP2D6; enantiomer; mirtazapine; pharmacogenetics; pharmacokinetics

Indexed keywords

DRUG METABOLITE; MIRTAZAPINE; N DESMETHYLMIRTAZAPINE; UNCLASSIFIED DRUG; CYTOCHROME P450 2D6; DESMETHYLMIRTAZAPINE; MIANSERIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CONCENTRATION AT STEADY-STATE; CYP2D6 GENE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENANTIOMER; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; JAPANESE (PEOPLE); LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SMOKING; STEREOCHEMISTRY; ANALOGS AND DERIVATIVES; BLOOD; DEPRESSIVE DISORDER; GENETICS; JAPAN; MIDDLE AGED; PHARMACOGENETICS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER; FEMALE; GENOTYPE; HUMANS; JAPAN; MALE; MIANSERIN; MIDDLE AGED; PHARMACOGENETICS; YOUNG ADULT;

EID: 84947928791     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0035-1565069     Document Type: Article

References (27)

1. de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol: 1995; 10 04 19 23
2. Timmer C. J., Sitsen J. M., Delbressine L. P. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet: 2000; 38 461 474
3. de Boer T., Nefkens F., Van Helvoirt A. The alpha 2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo. Eur J Pharmacol: 1994; 253 R5 R6
4. de Boer T. H., Nefkens F., van Helvoirt A. et al. Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther: 1996; 277 852 860
5. de Boer T. H., Maura G., Raiteri M. et al. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology: 1988; 27 399 408
6. Kooyman A. R., Zwart R., Vanderheijden P. M. et al. Interaction between enantiomers of mianserin and ORG3770 at 5-HT3 receptors in cultured mouse neuroblastoma cells. Neuropharmacology: 1994; 33 501 507
7. Timmer C. J., Paanakker J. E., VanHal HJ M. Pharmacokinetics of mirtazapine from orally administered tablets: Influence of gender, age and treatment regimen. Hum Psychopharmacol Clin and Exp: 1996; 11 497 509
8. Stormer E., von Moltke L. L., Shader R. I. et al. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos: 2000; 28 1168 1175
9. Dodd S., Boulton D. W., Burrows G. D. et al. In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes. Hum Psychopharmacol Clin Exp: 2001; 16 541 544
10. Jaquenoud Sirot E., Harenberg S., Vandel P. et al. Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. J Clin Psychopharmacol: 2012; 32 622 629
11. Delbressine L. P., Moonen M. E., Kaspersen F. M. et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Investig: 1998; 15 45 55
12. Dahl M. L., Voortman G., Alm C. et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Investig: 1997; 13 37 46
13. Brockmöller J., Meineke I., Kirchheiner J. Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. Clin Pharmacol Ther: 2007; 81 699 707
14. Sakuyama K., Sasaki T., Ujiie S. et al. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab Dispos: 2008; 36 2460 2467
15. The human cytochrome P450 (CYP) allele nomenclature database. Allele nomenclature for cytochrome P450 enzymes. (Accessed at http://www.cypalleles.ki.se/index.htm)
16. Broly F., Gaedigk A., Heim M. et al. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol: 1991; 10 545 558
17. Dahl M. L., Johansson I., Palmertz M. P. et al. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther: 1992; 51 12 17
18. Johansson I., Oscarson M., Yue Q. et al. Genetic analysis of the Chinese cytochrome P4502D6 locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for deberisoquine hydroxylation. Mol Pharmacol: 1994; 46 452 459
19. Mihara K., Otani K., Suzuki A. et al. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Psychopharmacol: 1997; 133 95 98
20. Suzuki A., Otani K., Mihara K. et al. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics: 1997; 7 415 418
21. Teh L. K., Bertilsson L. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet: 2012; 27 55 67
22. Paus E., Jonzier-Perey M., Cochard N. et al. Chirality in the new generation of antidepressants - Stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine, and 8-hydroxymirtazapine by LC-MS. Ther Drug Monit: 2004; 26 366 374
23. Steen V. M., Andreassen O. A., Daly A. K. et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics: 1995; 5 215 223
24. Morita S., Shimoda K., Someya T. et al. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese: The impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J Clin Psychopharmacol: 2000; 20 141 149
25. Shams M., Hiemke C., Härtter S. Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in human serum. Ther Drug Monit: 2004; 26 78 84
26. Lind A. B., Reis M., Bengtsson F. et al. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet: 2009; 48 63 70
27. Borobia A. M., Novalbos J., Guerra-Lopez P. et al. Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. Pharmacol Res: 2009; 59 393 398